


Product Name : JNJ-63576253
Cat. No. : PC-72511
CAS No. : 2110428-64-1
Molecular Formula : C₂₃H₂₂ClF₃N₆O₂S
Molecular Weight : 538.974
Target : Androgen Receptor (AR)
Solubility :



Biological Activity

JNJ-63576253 (TRC-253, JNJ63576253) is a next-generation, potent, selective androgen receptor (AR) antagonist (inhibitor) against wild-type AR (IC₅₀=6.9 nM), AR F877L and other clinically detected ligand binding domain (LBD) point mutations. JNJ-63576253 inhibits transcriptional activity in reporter assays, cellular proliferation, and AR downstream target gene expression.

JNJ-63576253 causes tumor growth inhibition (TGI) in an enzalutamide-resistant LNCaP F877 L xenograft model.

JNJ-63576253 displayed an approximately 1,000-fold selectivity versus other nuclear hormone receptors (GR IC₅₀>30 uM).

JNJ-63576253 completely inhibited transiently transfected VP16-AR F877 L with IC₅₀ of 15 nM in HepG2 transcriptional reporter models, JNJ-63576253 completely inhibited AR-mediated transactivation in the presence of 100 pmol/L R1881 (IC₅₀=99 nM).

JNJ-63576253 abrogates cellular proliferation, nuclear translocation, and AR target gene expression in models of human prostate adenocarcinoma.

JNJ-63576253 causes tumor growth inhibition (TGI) in an enzalutamide-resistant LNCaP F877 L xenograft model.

References

Zhang Z, et al. J Med Chem. 2021 Jan 28;64(2):909-924.

Branch JR, et al. Mol Cancer Ther. 2021 May;20(5):763-774.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com